RxDoctor Payments Data

Laura Shin, DPM

Podiatrist · Los Angeles, CANPI 1356756340

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,220 of the $19,856 with a category attached, or 76.7%. 19 manufacturers reported payments, led by Stryker at 38.5% of the total. 2025 is the largest year on record at $12,875, more than ten times the $349 reported in 2019. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,856in general payments, 2019–2025

Across 54 payments — averaging $367.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$8K
  • Advanced Oxygen Therapy Inc.$5K
  • Endo Pharmaceuticals Inc.$4K
  • Johnson & Johnson$780
  • Koya Medical, Inc.$594
  • Integra Lifesciences Corporation$391
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$15,22077%
  • Travel & lodging$1,6848%
  • Food & beverage$2,95215%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,856 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$164,870
Medicare patients
366
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole40$1,537
Gentamicin Sulfate20$1,159
Gabapentin51$623
Lidocaine13$528
Doxycycline Hyclate29$297
Pregabalin21$252
Tramadol Hcl18$44
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$39

Paid to pharmacies, not to this prescriber.

Other podiatrist in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →